The raphe nuclei are the primary source of serotonin (5-HT) in the brain and consist of nine median and dorsal raphe nuclei. Serotonergic neurons in these nuclei play crucial roles in mood regulation, sleep-wake cycles, and motor control. In Parkinson's disease (PD), these neurons undergo degeneration that contributes to both motor and non-motor symptoms.
The raphe nuclei contain distinct serotonin-producing neuronal populations:
- Dorsal raphe nucleus (DRN): The largest serotonergic cell group, containing medium-sized neurons with oval somata
- Median raphe nucleus (MRN): Contains larger serotonergic neurons that project to hippocampus and cortex
- ** caudal raphe nuclei**: Include the raphe magnus, pallidus, and obscurus, which project to the spinal cord
- Serotonergic neurons have characteristic dendritic arborization
- Axon terminals form dense synaptic contacts in target regions
- Neuronal size ranges from 15-30 μm in diameter
¶ Markers and Neurochemistry
Key markers for raphe serotonergic neurons:
- Tryptophan hydroxylase 2 (TPH2): Rate-limiting enzyme for 5-HT synthesis
- Serotonin transporter (SERT): Used for reuptake of 5-HT
- Vesicular monoamine transporter 2 (VMAT2): Packages 5-HT into vesicles
- Aromatic L-amino acid decarboxylase (AADC): Converts 5-HTP to serotonin
- 5-HT1A, 5-HT2A receptors: Autoreceptors regulating neuronal activity
Serotonergic neurons in PD are affected through several mechanisms:
- Alpha-synuclein pathology: Lewy bodies accumulate in raphe neurons
- Mitochondrial dysfunction: Complex I deficiency affects these neurons
- Neuroinflammation: Microglial activation in the raphe nuclei
- Axonal degeneration: Proximal to degenerating dopamine neurons
Serotonergic dysfunction contributes to:
- Levodopa-induced dyskinesias (when serotonergic neurons convert L-DOPA to dopamine)
- Gait dysfunction and postural instability
- Tremor generation through thalamic interactions
Depression and anxiety in PD are linked to:
- Reduced serotonergic innervation of prefrontal cortex
- Dysfunction of raphe-hippocampal pathways
- Altered sleep architecture due to raphe involvement in arousal systems
- Up to 50% of PD patients experience depression
- Serotonergic dysfunction is a primary mechanism
- SSRIs remain first-line treatment
- Raphe dysfunction contributes to REM sleep disinhibition
- Often precedes motor symptoms by years
- Indicates prodromal neurodegeneration
- Serotonergic system involved in fatigue generation
- May relate to brainstem involvement early in disease
¶ SSRIs and SNRIs
Selective serotonin reuptake inhibitors help:
- Alleviate depression in PD
- May have modest motor benefits
- Caution needed for drug interactions
Buspirone and related compounds:
- May reduce levodopa-induced dyskinesias
- Act as autoreceptor agonists
- Reduce serotonin release
DBS affects serotonergic systems:
- Subthalamic nucleus DBS may impact raphe function
- Pedunculopontine nucleus DBS affects brainstem serotonergic circuits
- Jellinger KA. The pathology of Parkinson's disease. Advances in Neurology. 2001
- Politis M, et al. Serotonergic dysfunction in Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry. 2012
- Pavese N, et al. Serotonergic pathology in Parkinson's disease. Brain. 2011